Skip to main content

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, dial (877) 621-5803; the conference ID is 1587202. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.07
-0.72 (-0.35%)
AAPL  260.43
-3.92 (-1.48%)
AMD  202.36
+2.24 (1.12%)
BAC  52.43
-0.93 (-1.74%)
GOOG  303.78
-0.16 (-0.05%)
META  643.53
+0.31 (0.05%)
MSFT  396.94
-2.66 (-0.67%)
NVDA  186.58
-1.40 (-0.74%)
ORCL  156.06
-0.10 (-0.07%)
TSLA  409.91
-1.41 (-0.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.